1369256-71-2

Basic information

• Product Name: (3,5-difluoro-4-((6-(trifluoromethyl)-3-pyridinyl)oxy)phenyl)methanol
• Synonyms: (3,5-difluoro-4-((6-(trifluoromethyl)-3-pyridinyl)oxy)phenyl)methanol
• CAS NO: 1369256-71-2
• Molecular Weight: 305.204
• Mol File: 1369256-71-2.mol
• Article Data: 13

Chemical Properties

• CAS DataBase Reference: (3,5-difluoro-4-((6-(trifluoromethyl)-3-pyridinyl)oxy)phenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (3,5-difluoro-4-((6-(trifluoromethyl)-3-pyridinyl)oxy)phenyl)methanol(1369256-71-2)
• EPA Substance Registry System: (3,5-difluoro-4-((6-(trifluoromethyl)-3-pyridinyl)oxy)phenyl)methanol(1369256-71-2)

Safety Data

• Hazardous Substances Data: 1369256-71-2(Hazardous Substances Data)

Upstream product

• 216766-12-0 5-hydroxy-2-trifluoromethyl pyridine 
• 132123-54-7 3,4,5-trifluorobenzaldehyde 
• 1369256-70-1 3,5-difluoro-4-((6-(trifluoromethyl)-3-pyridinyl)oxy)benzaldehyde 

Downstream Products

• 1420367-28-7 8-((3,5-difluoro-4-((6-(trifluoromethyl)pyridin-3-yl)oxy)benzyl)oxy)-1-methyl-3,4-dihydro-1H-pyrimido[1,6-a]pyrimidin-6(2H)-one 

Relevant articles and documents

Tetracyclic pyrimidinone compound, preparation method, composition and application thereof

A tetracyclic pyrimidinone compound represented by a formula (I) or a pharmaceutically acceptable salt thereof has a structure represented by a formula (I), is a brand new Lp-PLA2 inhibitor, and can be used for treating neurodegenerative related diseases such as Alzheimer's disease (AD), glaucoma, age-related macular degeneration (AMD), or cardiovascular diseases including atherosclerosis and thelike.

Tricyclic dihydroimidazopyrimidinone derivative, and preparation method, pharmaceutical composition and application thereof

The invention provides a compound as shown in a general formula (I), cis-trans isomers, enantiomers, diastereoisomers, racemes, solvates, hydrates or pharmaceutically acceptable salts or prodrugs of the compound, a preparation method of the compound, a pharmaceutical composition containing the compound and an application of the compound as aLp-PLA2 inhibitor, wherein R1, R2, Rx, Ra, Q, U, X, Y, m, n and A are defined in the specification.

COMPOUNDS

The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example Alzheimer's disease.